Olfactory receptor OR2L8: a drug target and biomarker (G391190)
Olfactory receptor OR2L8: a drug target and biomarker
Smell is a crucial sense, and our ability to sense and identify different scents is vital for our survival. Olfactory receptors, which are present in the nose, help us identify and remember different smells. In this article, we will discuss Olfactory receptor OR2L8, a drug target and biomarker that plays a crucial role in human olfactory system.
OR2L8: the olfactory receptor OR2L8 is a transmembrane protein that is expressed in the vom vasculature epithelial cells and nasal epithelial cells. It is one of the six olfactory receptors that are responsible for mediating the sense of smell. OR2L8 is a G protein-coupled receptor (GPCR), which means it uses a protein called G protein to communicate with other cells in the body.
OR2L8 is a key regulator of the sense of smell. When we smell a scent, the OR2L8 protein is activated, and the GPCR signaling pathway is activated. The GPCR signaling pathway involves a series of chemical interactions between the OR2L8 protein and other proteins on the surface of the cells. This interaction allows the OR2L8 protein to transmit signals from the nose to the brain, where the sense of smell is processed and interpreted.
OR2L8 is a drug target for several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its potential as a drug target is due to its unique mechanism of action and its expression in different tissues.
OR2L8 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.
First, OR2L8 has been linked to cancer. Several studies have shown that high levels of OR2L8 are associated with an increased risk of several types of cancer, including breast, ovarian, and prostate cancer. This is because when OR2L8 is activated, it can lead to the formation of new blood vessels, which can contribute to the development of cancer.
Second, OR2L8 is involved in neurodegenerative diseases. Alzheimer's disease is a neurodegenerative disorder that is characterized by the progressive loss of brain cells. Several studies have shown that OR2L8 is involved in the development and progression of Alzheimer's disease. This is because when OR2L8 is activated , it can contribute to the formation of neurofibrillary tangles and other hallmark pathological changes in the brain that are associated with Alzheimer's disease.
Third, OR2L8 is also involved in psychiatric disorders. Studies have shown that OR2L8 is involved in the treatment of depression and anxiety disorders. This is because when OR2L8 is activated, it can help regulate the production of certain neurotransmitters, such as serotonin and dopamine, which are involved in mood and anxiety.
Despite its potential as a drug target, OR2L8 is also a potential biomarker for several diseases. For example, it has been shown to be involved in the development of glaucoma, a leading cause of blindness. This is because when OR2L8 is activated, it can contribute to the formation of new blood vessels that can contribute to the development of glaucoma.
In conclusion, Olfactory receptor OR2L8 is a drug target and biomarker that plays a crucial role in the human sense of smell. Its unique mechanism of action and its expression in different tissues make it an attractive target for drug development. Further research is needed to fully understand the role of OR2L8 in diseases and its potential as a biomarker.
Protein Name: Olfactory Receptor Family 2 Subfamily L Member 8
Functions: Odorant receptor
The "OR2L8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2L8 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P
